Archive

GLP-1 drugs linked to reduced risk of epilepsy

Written by Bruce Sylvester | 14 Dec 2025

A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy. The findings appeared… read more.

Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles in clinical settings

Written by Charlie King | 13 Nov 2025

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that… read more.

The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss

Written by Charlie King | 30 Oct 2025

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight… read more.

Half of patients taking weight-loss drug quit within a year

Written by Gary Finnegan | 27 Sep 2025

More than half of all adults without diabetes who began taking semaglutide discontinued treatment within a year, according to new research on Danish patients. The population-wide study was… read more.

Semaglutide provides powerful protection against diabetic retinopathy, the leading cause of blindness in working-age adults, Greek study suggests

Written by Charlie King | 24 Sep 2025

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting… read more.

Half of people stop taking popular weight-loss drug within a year, national study finds

Written by Charlie King | 20 Sep 2025

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at… read more.

GLP-1 drugs reduce risk of death and hospitalization in patients with heart failure

Written by Charlie King | 7 Sep 2025

Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity… read more.

One in seven bariatric surgery patients turn to new weight loss drugs

Written by Charlie King | 31 Aug 2025

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like… read more.

Wegovy (semaglutide 2.4 mg) approved in the US for the treatment of MASH – Novo Nordisk

Written by Charlie King | 21 Aug 2025

Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.

Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

Written by Charlie King | 28 May 2025

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress… read more.

First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide

Written by Charlie King | 18 May 2025

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an… read more.

New oral GLP-1RA orforglipron comparable to semaglutide for weight loss

Written by Christine Clark | 22 Apr 2025

Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.

1 2 3 … 5 Next »

Archive

Subscribe for our mailing list

Follow Us